Table 1.

Selected drugs potentially targeting cancer-associated fibroblasts (CAFs) or the extracellular matrix (ECM) in preclinical and clinical studies

Drugs	Target and mechanism	Cancer types	National Clinical Trial number	Status	Ref.
Sibrotuzumab	131I-labeled anti-FAP mAb	Colorectal, non-small cell lung, breast, or head and neck cancers	NCT02198274 NCT02209727	Phase I	183
Calcipotriol Paricalcitol	Vitamin D analogue	Early-stage skin cancer, breast cancer, pancreatic cancer	NCT03596073 NCT04617067 NCT02030860 NCT03138720 NCT04054362	Phase I/II	40
Pamrevlumab (FG-3019)	Anti-CTGF mAb	Pancreatic cancer	NCT03941093	Phase III	184
Plerixafor (AMD3100) BL-8040 (motixafortide)	CXCR4 receptor antagonist	Pancreatic cancer	NCT04177810 NCT02179970 NCT02826486 NCT03193190	Phase I/II	30,45
IPI-926	Smoothened inhibitor	Pancreatic cancer	NCT01130142	Phase I	185
S-3304	MMP inhibitor	Advanced solid tumors	NCT00078390 NCT00033215	Phase I	48
131I-m81C6	131I-labeled anti-tenascin mAb	Brain tumors	NCT00002752 NCT00003461	Phase II	186
Imatinib	PDGFR inhibitor	Advanced solid tumors	NCT00161213 NCT00281996 NCT01048320 NCT00485485	Phase I/II	187
GS-6624 (simtuzumab)	LOXL2 mAb	Pancreatic cancer	NCT01472198 NCT01479465	Phase II	52
Tetrathiomolybdate	Copper chelator, target LOX	Breast cancer, prostate cancer	NCT00195091 NCT00150995 NCT00405574	Phase II	188
pegvorhyaluronidase alfa (PEGPH20; PVHA)	Recombinant Human Hyaluronidase	Lung cancer, Pancreatic cancer,	NCT01453153 NCT02563548 NCT01839487 NCT02715804	Phase I/II/III